ABSTRACT
Maintaining surveillance of emerging infectious diseases presents challenges for monitoring their transmission and burden. Incomplete observation of infections and imperfect diagnosis reduce the observed sizes of transmission chains relative to their true sizes. Previous studies have examined the effect of incomplete observation on estimates of pathogen transmission and burden. However, each study assumed that, if observed, each infection was correctly diagnosed. Here, I leveraged principles from branching process theory to examine how misdiagnosis could contribute to bias in estimates of transmission and burden for emerging infectious diseases. Using the zoonotic Plasmodium knowlesi malaria as a case study, I found that, even when assuming complete observation of infections, the number of misdiagnosed cases within a transmission chain for every correctly diagnosed case could range from 0 (0 – 4) when R0 was 0.1 to 86 (0 – 837) when R0 was 0.9. Data on transmission chain sizes obtained using an imperfect diagnostic could consistently lead to underestimates of R0, the basic reproduction number, and simulations revealed that such data on up to 1,000 observed transmission chains was not powered to detect changes in transmission. My results demonstrate that misdiagnosis may hinder effective monitoring of emerging infectious diseases and that sensitivity of diagnostics should be considered in evaluations of surveillance systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
I acknowledge funding from a Graduate Research Fellowship from the National Science Foundation and a Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame. The funders had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the design to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research does not involve human subjects so does not require IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code and data to reproduce the analyses will be available upon publication.
